Suppr超能文献

新型强效酰基辅酶A:胆固醇O-酰基转移酶抑制剂F 12511对培养的人肾上腺皮质细胞无毒性作用。

Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture.

作者信息

Junquero D, Pilon A, Carilla-Durand E, Patoiseau J F, Tarayre J P, Torpier G, Staels B, Fruchart J C, Colpaert F C, Clavey V, Delhon A

机构信息

Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin, F-81106 Castres Cédex, France.

出版信息

Biochem Pharmacol. 2001 Feb 15;61(4):387-98. doi: 10.1016/s0006-2952(00)00555-4.

Abstract

Inhibition of acyl-coenzyme A: cholesterol O-acyltransferase (EC 2.3.1.26; ACAT) reduces intracellular cholesteryl esters that are substrates for steroidogenesis in adrenal cells. The adrenal side effects of ACAT inhibitors remain a key point for their development as antiatherosclerotic agents. The aim of this study was to characterize the effects of a novel and powerful ACAT inhibitor, F 12511 (S)-2',3',5'-trimethyl-4'-hydroxy-alpha-dodecylthio-phenylacetanilide, on the NCI-H295R cell line, which has functional properties comparable to those of normal human adrenal cells. F 12511 incubated with cultured cells for 4-72 hr strongly inhibited cholesteryl oleate formation. The concentrations required to produce 50% inhibition (IC50) values) ranged from 20 to 50 nM; in the presence of low-density lipoproteins (LDL), this effect was paralleled by a decrease in cholesteryl ester mass and an increase in intracellular free cholesterol. At concentrations 100-fold larger than the IC(50) value for up to 48 hr, F 12511 reduced neither the basal release of cortisol and aldosterone nor the production of cortisol stimulated by forskolin. F 12511 did not modify the mRNA levels of the steroidogenic enzyme genes cytochrome P450 cholesterol side-chain cleavage (P450scc), cytochrome P450 17alpha-hydroxylase (P450c17), or cytochrome P450 21-hydroxylase (P450c21) or those of the LDL receptor and high-density lipoprotein scavenger receptor class B, type I (SR-BI) genes, either in the presence or absence of adenosine 3',5'-cyclic monophosphate stimulation for 24 hr. Exposure to F 12511 at up to 3 microM for 24 or 48 hr did not result in significant change in morphological and ultrastructural characteristics; the cytoplasm contained large numbers of mitochondria with intact crystae, and the same typical features of secretory activity were observed in NCI-H295R control cells. Exposure to 3 microM of F 12511 for 96 hr also did not affect cell viability. These data demonstrate that reduction of the substrate for steroidogenesis by the ACAT inhibitor F 12511 impairs neither steroid production nor transcription of genes involved in steroidogenesis and lipoprotein uptake in the pluripotent human adrenal cell line NCI-H295R.

摘要

抑制酰基辅酶A:胆固醇O-酰基转移酶(EC 2.3.1.26;ACAT)可减少细胞内胆固醇酯,而胆固醇酯是肾上腺细胞中类固醇生成的底物。ACAT抑制剂的肾上腺副作用仍是其作为抗动脉粥样硬化药物开发的关键问题。本研究的目的是表征新型强效ACAT抑制剂F 12511(S)-2',3',5'-三甲基-4'-羟基-α-十二烷基硫代苯乙酰胺对NCI-H295R细胞系的影响,该细胞系具有与正常人肾上腺细胞相当的功能特性。F 12511与培养细胞孵育4至72小时可强烈抑制油酸胆固醇酯的形成。产生50%抑制作用所需的浓度(IC50值)范围为20至50 nM;在低密度脂蛋白(LDL)存在的情况下,这种作用伴随着胆固醇酯质量的减少和细胞内游离胆固醇的增加。在比IC50值高100倍的浓度下处理长达48小时,F 12511既不降低皮质醇和醛固酮的基础释放量,也不降低福斯可林刺激的皮质醇生成量。F 12511在存在或不存在3',5'-环磷酸腺苷刺激24小时的情况下,均未改变类固醇生成酶基因细胞色素P450胆固醇侧链裂解酶(P450scc)、细胞色素P450 17α-羟化酶(P450c17)或细胞色素P450 21-羟化酶(P450c21)的mRNA水平,也未改变LDL受体和高密度脂蛋白清道夫受体B类I型(SR-BI)基因的mRNA水平。在高达3 microM的浓度下暴露于F 12511 24或48小时,形态和超微结构特征未发生显著变化;细胞质中含有大量嵴完整的线粒体,NCI-H295R对照细胞中观察到相同的典型分泌活性特征。在3 microM的F 12511中暴露96小时也不影响细胞活力。这些数据表明,ACAT抑制剂F 12511减少类固醇生成底物的同时,不会损害多能人类肾上腺细胞系NCI-H295R中的类固醇生成或参与类固醇生成和脂蛋白摄取的基因转录。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验